Paper Details

  1. Home
  2. Paper Details

Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review.

Author: AlbiniThomas, ChangMichael, KopplinLaura J, StiefelHillary C, SuhlerEric B, VeguntaSravanthi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pegylated interferon alfa-2A is a potential treatment for refractory inflammatory cystoid macular edema (CME). In this retrospective study, seven patients with CME showed improvement in central macular thickness (CMT) and visual acuity after treatment, although some experienced side effects.
Paper Details　
Original Abstract of the Article :
<i>Purpose</i>: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME)<i>Methods</i>: Retrospective chart review<i>Results</i>: Treatment with pegylated interferon alfa-2A led to an improvement in CME in all eyes of seven in...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09273948.2019.1687729

データ提供：米国国立医学図書館（NLM）

Treating Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A

This research delves into the field of [ophthalmology] and investigates the effectiveness of [pegylated interferon alfa-2A] in treating [refractory inflammatory cystoid macular edema (CME)]. The study utilizes a [retrospective chart review] approach to examine the clinical data of patients who received this treatment. The authors report that [pegylated interferon alfa-2A led to an improvement in CME in all seven patients included in the study]. The findings suggest that this treatment can be effective in managing refractory CME, although some patients may experience [side effects] that limit tolerability.

The Promise of Pegylated Interferon Alfa-2A for CME

This study highlights the potential of pegylated interferon alfa-2A as a treatment option for refractory CME. The findings suggest that this treatment can effectively reduce CME and improve visual acuity in some patients, although further research is needed to optimize treatment strategies and address potential side effects.

Managing Cystoid Macular Edema

Just as a desert traveler may encounter mirages that distort the landscape, CME can distort vision and affect quality of life. This research offers hope for individuals struggling with refractory CME, showcasing the potential of pegylated interferon alfa-2A to restore vision and improve well-being.

Dr.Camel's Conclusion

Imagine a desert oasis reflecting the sun, creating an alluring but deceptive mirage. Similarly, CME can distort our vision, affecting our perception of the world. This research, like a skilled desert guide, sheds light on a potential treatment for refractory CME, offering hope and a clearer path towards restored vision.
Date :
  1. Date Completed 2022-01-21
  2. Date Revised 2022-01-21
Further Info :

Pubmed ID

31743052

DOI: Digital Object Identifier

10.1080/09273948.2019.1687729

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.